imatinib mesylate has been researched along with Central Nervous System Neoplasm in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (63.64) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Hatta, Y; Hayakawa, F; Yamazaki, E | 1 |
| Hirano, M; Imai, Y; Imoto, S; Jimbo, K; Kawamata, T; Miyano, S; Ochi, K; Ogawa, M; Ohno, N; Shimizu, E; Takahashi, N; Tojo, A; Uchimaru, K; Yamaguchi, R; Yokoyama, K; Yokoyama, N | 1 |
| Gupta, B; Kumar, A; Pant, G; Pooniya, V; Sharma, A; Verma, N | 1 |
| Ahn, JY; Jeong, JH; Jeong, JW; Kim, KH; Kim, MJ; Park, J; Park, MJ; Park, PW; Seo, JY; Seo, YH | 1 |
| Seth, R; Thavaraj, V | 1 |
| Bartels, U; Baruchel, S; Bouffet, E; Egorin, MJ; Fryer, C; Gammon, J; Halton, J; Hawkins, C; Hukin, J; Martinho, O; Odame, I; Portwine, C; Reis, RM; Sharp, JR; Stempak, D; Strother, D | 1 |
| Ahluwalia, MS; Battiwalla, M; Cohen, IL; Francis, J; McCarthy, PL; Paplham, P; Smiley, S; Spangenthal, E; Wang, E; Wetzler, M | 1 |
| Chondropoulos, S; Dervenoulas, J; Economopoulos, T; Economopoulou, C; Ionnidou, ED; Konsioti, F; Papageorgiou, E; Papageorgiou, SG; Pappa, V; Tsirigotis, P; Vasilatou, D | 1 |
| Fielding, AK | 1 |
| Cantú-Rodríguez, O; García-Rodríguez, F; Gómez-Almaguer, D; González-Llano, O; Gutiérrez-Aguirre, H; Jaime-Pérez, J | 1 |
| Ikeda, Y; O'Brien, SG; Okamoto, S; Sato, N; Takayama, N | 1 |
| Binckebanck, A; Brück, P; Gökbuget, N; Gschaidmeier, H; Hoelzer, D; Hofmann, WK; Komor, M; Leimer, L; Lübbert, M; Ottmann, OG; Pfeifer, H; Scheuring, U; Schleyer, E; Wassmann, B; Wolff, T | 1 |
| Bujassoum, S; Lipton, JH; Rifkind, J | 1 |
| Curtin, PT; Druker, BJ; Ford, JM; Leis, JF; Maziarz, RT; Peng, B; Schubach, S; Stepan, DE | 1 |
| Hirase, C; Kanamaru, A; Maeda, Y; Matsuda, M; Miyatake, J; Morita, Y; Shimada, T; Tanaka, M; Tatsumi, Y | 1 |
| Caplan, SN; Fetni, R; Johnson, NA | 1 |
| Chiusolo, P; De Matteis, S; De Vita, S; Fiorini, A; Laurenti, L; Leone, G; Reddiconto, G; Sica, S | 1 |
| Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, A; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Altintas, A; Ayyildiz, O; Cil, T; Kaplan, MA; Kilinc, I | 1 |
| Agis, H; Aichberger, KJ; Esterbauer, H; Haas, OA; Herndlhofer, S; Jäger, U; Knöbl, P; Rabitsch, W; Schwarzinger, I; Sillaber, C; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Cortes, J; Kantarjian, H; Kebriaei, P; O'Brien, S; Ravandi, F; Thomas, D; Vega-Ruiz, A | 1 |
| Cuvelier, GD; Dix, DB; Ford, JC; Vitali, AM | 1 |
3 trial(s) available for imatinib mesylate and Central Nervous System Neoplasm
| Article | Year |
|---|---|
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Canada; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2009 |
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
Topics: Adult; Benzamides; Blast Crisis; Blood-Brain Barrier; Central Nervous System Neoplasms; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Tissue Distribution; Treatment Outcome | 2004 |
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Central Nervous System Neoplasms; Female; Follow-Up Studies; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2007 |
19 other study(ies) available for imatinib mesylate and Central Nervous System Neoplasm
| Article | Year |
|---|---|
JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Consolidation Chemotherapy; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Philadelphia Chromosome; Practice Guidelines as Topic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome; World Health Organization; Young Adult | 2020 |
Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Neoplasms; Central Nervous System Neoplasms; Dasatinib; Drug Administration Schedule; Drug Substitution; Fatal Outcome; Female; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pyridazines; Pyrimidines; Recurrence | 2018 |
Demographics and Outcome of Philadelphia-positive ALL in a Pediatric Population in North India: a Single-center Experience.
Topics: Bone Marrow Examination; Central Nervous System Neoplasms; Child; Female; Humans; Imatinib Mesylate; India; Kaplan-Meier Estimate; Leukocyte Count; Male; Neutropenia; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Analysis; Treatment Outcome | 2019 |
A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib.
Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2014 |
Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood Cell Count; Central Nervous System Neoplasms; Chemoprevention; Child; Clinical Protocols; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Methotrexate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction | 2008 |
Reversible cardiotoxicity with tyrosine kinase inhibitors.
Topics: Adult; Benzamides; Cardiotoxins; Central Nervous System Neoplasms; Dasatinib; Fatal Outcome; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Ventricular Dysfunction, Left | 2010 |
Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression.
Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Megakaryoblastic, Acute; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Thiazoles | 2010 |
How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2010 |
Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous; Young Adult | 2011 |
Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.
Topics: Adult; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Central Nervous System Neoplasms; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2002 |
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Clinical Trials as Topic; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Metastasis; Phenotype; Piperazines; Prognosis; Pyrimidines; Risk; Risk Factors; Time Factors; Treatment Outcome | 2003 |
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction | 2004 |
Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Central Nervous System Neoplasms; Clone Cells; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2005 |
Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Central Nervous System Neoplasms; Chronic Disease; Fatal Outcome; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2005 |
Secondary Ph+ acute lymphoblastic leukemia after temozolomide.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Temozolomide | 2005 |
Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood-Brain Barrier; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Methotrexate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Myeloid; Treatment Outcome | 2007 |
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Central Nervous System Neoplasms; Cytarabine; Dasatinib; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liposomes; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Cyclophosphamide; Cytogenetic Analysis; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome; Vincristine | 2008 |
Multiple intracranial tumors in Philadelphia chromosome positive acute lymphoblastic leukemia: successful treatment following aggressive supportive care, early cranial radiation, high dose chemotherapy and imatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Central Nervous System Neoplasms; Child; Cranial Irradiation; Female; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction | 2008 |